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1. Introduction 
Following the demonstration by Robinson and 
Stirling [l] of two hexosaminidase components, A 
and B, in human spleen, similar components have 
been found in all human tissues investigated [2,3] 
and, with one exception [4], it is now well-established 
that patients with early-infantile kZ -gangliosidosis* 
are totally deficient in hexosaminidase A [3,4,6] . 
However, the recognition of closely related variants 
has led to some confusion when the clinical term 
“Tay-Sachs disease” is used to designate %a -gang 
liosidoses; a note on their nomenclature is therefore 
included. 
In the present study, the separation of hexosami- 
nidase components of post-mortem brain grey matter 
by gradient elution from DEAE-cellulose is described. 
The patterns obtained in five cases of GZ gangliosi- 
dosis were compared with four controls. The con- 
trols all had a very similar enzyme pattern; two 
major peaks of activity, corresponding to components 
A and B reported in previous studies [ 1 ] , were 
clearly separated from several smaller intermediate 
fractions. The pattern in each of the five cases dif- 
fered from the controls, and three types could be 
distinguished. 
* The ganglioside nomenclature used in this report is that of 
Svennerhtdm [ 51. 
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2. Materials and methods 
2.1. Materials 
Specimens of frontal cortex were frozen with solid 
carbon dioxide several hours after death and stored 
at -20” until examined. 
2.2. Identification of gangliosides 
Gangliosides in chloroform-methanol (2: 1, v/v) 
extracts were separated by thin-layer chromatogra- 
phy on silica gel G with chloroform-methanol-l .4 M 
NH3 (55:40: 10, by vol.). Hexosides were separated 
with chloroform-methanol-water (70:30:5, by vol.). 
2.3. DEAE-Cellulose chromatography 
The method was based on that used by Robinson, 
Price, and Dance [7] for rat kidney enzymes. Super- 
natant (2 ml) from a 5% w/v homogenate of grey 
matter in phosphate buffer (10 mM Na2HP04 adjusted 
to pH 6.0 with phosphoric acid) was loaded onto a 
column (28 cm X 1.5 cm i.d.) of Whatman DEAB- 
cellulose, type DE52 ON. and R.Balston Ltd) equi- 
librated with the phosphate buffer at 4”. A linear 
NaCl gradient in the same buffer was immediately 
applied and 5 ml fractions were collected at a flow 
rate of 12 ml/hr. 
2.4. Starch-gel electrophoresis 
The conditions were those of Robinson, Price and 
Dance [7]. 
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2.5. Assay of hexosaminidase activity 
The method was a modification of that of Leaback 
and Walker [8] : enzyme solution (100 /.d) was in- 
cubated with 3 mM 4-methyl-umbellifery12-acetamido- 
2-deoxy_P-D-glucopyranoside (Koch-Light Laborato- 
ries Ltd) in sodium phosphate-citrate buffer, pH 4.5 
[9] (100 ~1) at 37” for 20 min; 0.25 M glycine adjusted 
to pH 10.4 with NaOH (1 .O ml) was then added and 
the fluorescence measured in an Aminco-Bowman 
spectrofluorimeter, excitation, 360 nm; emission, 440 
nm. 
3. Results and discussion 
Hexosaminidase components A and B separate as 
two broad bands on starch-gel electrophoresis of 
homogenates of normal brain. However, a more com- 
plex pattern was obtained after fractionation by grad- 
ient elution from DEAE-cellulose, as shown in fig. 1 
and summarized in table 1. The hexosaminidase 
component defined as A in the electrophoretic se- 
paration [7] is equivalent to the last peak of acti- 
vity eluted from the DEAE-column. 
The presence of several minor peaks of activity 
was also indicated by isoelectric focussing [4]. 
Since hexosaminidase A can be degraded by neur- 
aminidase to a form electrophoretically identical to 
hexosaminidase B [l] , it is possible that these minor 
peaks represent hexosaminidase components with 
intermediate numbers of N-acetylneuraminic acid 
residues. 
The clinical and chemical findings in the five 
cases studied are summarized in table 2. The resul- 
ting classification into three types was fully suppor- 
ted by studies on the brain hexosaminidase patterns 
as shown in fig. 1 and table 1, and confirms recent 
reports of the occurrence of these variants [4, lo] . 
The finding that the hexosaminidase activity can 
be resolved by DEAE-cellulose chromatography in- 
Fraction No. (Sml per fraction) 
Fig. 1. Fractionation of brain hexosaminidase on DEAEcellulose. 6-a Control; - Case 1, early-infantile GM2-ganghosidosis; 
A---A Case 5, late-infantile CM2-gangliosidosis. All fractions from Case 4, early-infantile GMa-gangliosidosis, were inactive. Hexos- 
aminidase activity is expressed as nmoles substrate hydrolyzed per hour per 100 ~1 of individual fractions in the standard assay sys- 
tem . 
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Table 1 
Fractionation ofN-acetyl-p-hexosaminidase components by DEAE-cellulose chromatography. 
Fraction 
numbers 
Equivalent 
component by 
starch gel 
electropho- 
resis 
Equivalent 
component by 
isoelectric 
focussing 
Relative distribution of components 
Controls 
GMa-gangliosidosis’ 
Cases 1,2,3 Case 5 
4to 6 
Component with 
isoelectric point 
pH 7.4 
Major peak 
- 
20 to 35 B 
Two minor 
peaks 
Broad, low 
peak with 
indication of 
more than one 
component 
36 to 50 A 
Component with 
isoelectric 
point pH 5 .O 
Major peak 
Greatly elevated 
Incompletely 
resolved from 
first major peak 
Same position as 
for controls but 
about double the 
activity 
Absent 
Slightly elevated 
As for controls 
As for controls 
Same position as 
for controls but 
about one third of 
the activity 
*No activity found in any fraction from Case 4. 
to more than the two components seen after electro- 
phoretic separation could be important in diagnosis 
as well as in the elucidation of possible molecular e- 
lationships between these components. It might en- 
able new variants to be recognised and should increase 
the reliability of the diagnosis in cases of late infantile 
C& gangliosidosis nwhich the deficiency of hexos- 
aminidase 4 is incomplete (see fig. 1). 
In addition to the three types of %a -gangliosi- 
dosis listed in table 2, two further variants have been 
Table 2 
Summary of clinical and biochemical findings. 
Case number Clinical presentation Lipid stored Suggested systematic nomenclature* 
1,293 
Early-infantile onset. 
Conventional symptoms of 
Tay-Sachs disease 
GM2 
GM2-gangbOSidOSiS, Type AoBH 
Early-infantile onset. 
Conventional symptoms 
of Tay-Sachs disease 
GM? and 
globoside 
Late-infantile onset. 
GM*-ganghosidosis, Type AoBo 
5 
Symptoms similar to 
case described by Volk 
et al. [13] 
GM2 GMz-gangliosidosis, Type ALBN 
* see Section 4. 
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described. The first of these was reported by Sand- 
hoff [4] to be clinically identical to typical cases of 
TaySachs disease, to store ganglioside $ in nerve 
tissue, and to have normal proportions of !l exosami- 
nidase components A and B, though both were ele- 
vated. The other variant was reported by Suzuki [l l] 
as a case of “juvenile GM2 -gangliosidosis”. Although 
the total hexosaminidase activities of brain, liver, and 
spleen were normal, a study of the relative activities 
of components A and B has not yet been reported. 
This case had many features in common with the late- 
infantile variant and may also be found to have a si- 
milar partial deficiency of hexosaminidase A. We can 
report a similar case from this hospital of a girl whose 
symptoms first appeared at the age of 9 years and who 
died aged 14 years. Although only formalin-fixed 
brain was available for analysis, storage of GM2 -gang- 
lioside was clearly demonstrated. 
4. A note on the nomenclature of the gangliosidoses 
The generally accepted classification of the gang- 
liosidoses according to the nature of the lipid stored 
was first proposed by Suzuki and Chen [ 121. They 
recognised that subdivision might become necessary 
as knowledge advanced and, with the recent findings 
and possible further discovery of specific enzyme 
abnormalities in closely related variants of-&s gang- 
liosidoses, such subdivision is now required. O’Brien 
[lo] has referred to these variants as “Types 1,2 and 
3” but it is desirable to employ a comprehensive 
system of nomenclature from which the nature of 
the specific enzyme defect is apparent. We therefore 
propose the modification shown in the right-hand 
column of table 2, where A and B refer to the two 
major components of hexosaminidase and subscripts 
show the nature of the abnormality: H(high), N(nor- 
mal), L(Low), and O(no activity). 
The unusual case reported by Sandhoff [4] would 
be designated as “ks -gangliosidosis, Type A$$+“. 
A similar system of nomenclature could be used to 
define other conditions involving varying deficiencies 
of a multi-component enzymic activity. 
A comment on the use of the clinical designation 
“Tay-Sachs disease” is necessary in view of the de- 
monstrably different conditions to which it is now 
applied; three distinct uses of the term are found in the 
literature: i) for all cases of&s -gangliosidosis; ii) for 
early infantile kZ -gangliosidosis; iii) for only those 
cases of early infantile %a -gangliosidosis in which 
hexosaminidase component A is absent and component 
B present. Volk and his colleagues [ 131 concluded 
that late-infantile &s -gangliosidosis is clinically 
distinct from typical cases of Tay-Sachs disease 
and this distinction applies equally to juvenile kZ - 
gangliosidosis [ 111. Use (i) above is therefore inap- 
propriate. Since those cases lacking both A and B 
components of hexosaminidase are clinically iden- 
tical with cases lacking only component A, the clinical 
term “TaySachs disease” applies equally to both and 
will certainly continue to be used for these conditions, 
as in (ii) above. The differences between these variants 
are made apparent by the use of the systematic nomen- 
clature suggested above. 
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